Physician profile
Timothy Quezada
NPI 1871942326
$2,017.22
in general payments reported to CMS, 2019-2025
14 companies · $36.53 in 2025
The $36.53 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $380 · 2021: $159 · 2023: $233 · 2024: $833 · 2025: $36.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $529.20 | 2020-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $388.73 | 2021-2024 | |
| Emd Serono, INC. | $245.69 | 2024 | |
| Ucb, INC. | $179.34 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $143.37 | 2019 | |
| Allergan, INC. | $123.24 | 2020 | |
| Microtransponder, INC. | $122.06 | 2024 | |
| Sunovion Pharmaceuticals INC. | $109.79 | 2019 | |
| Neuropace, INC. | $84.58 | 2023 | |
| Medtronic, INC. | $22.88 | 2024 | Sensight |
| Neurelis, INC. | $20.64 | 2024 | Valtoco |
| Abbvie INC. | $18.47 | 2025 | |
| Acadia Pharmaceuticals INC | $18.06 | 2025 | Nuplazid |
| Genentech USA, INC. | $11.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Quezada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.